G207

AXP000074.1 · Oncolytic virus

Platform
HSV-1 (strain F, gamma34.5-deleted, ICP6-inactivated)
Originator
Georgetown University (Robert Martuza)
Sponsor
Treovir LLC

Names

NameTypeSource
G207preferred name, codecurator, ncit
HSV G207synonymctgov

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Strain
F
Replication
conditionally replicating
Modifications
both copies of gamma34.5 (RL1) deleted; UL39 (ICP6) inactivated by lacZ insertion
Transgenes
LacZ
Route
intratumoral, intracerebral
Source
evidence

Cross-references

NCI Thesaurus
C2676

Approvals

No regulatory approval recorded.

Clinical trials (6)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07649070Phase 2 Trial of G207 + 5 Gy Radiation for Children With High-Grade GliomasRecruitingPhase 22026-10-122030-12-3138High Grade Gliomas
NCT04482933HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade GliomaWithdrawnPhase 22025-09-012025-12-180Anaplastic Astrocytoma of Brain; Anaplastic Glioma; Giant Cell Glioblastoma; Glioblastoma Multiforme; High Grade Glioma; High-grade Glioma; Malignant Glioma of Brain; Neoplasms
NCT03911388HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsRecruitingPhase 12019-09-122026-09-0124Astrocytoma; Astrocytoma, Cerebellar; Brain Diseases; Central Nervous System Diseases; Central Nervous System Neoplasms, Malignant; Central Nervous System Neoplasms, Primary; Cerebellar Neoplasm Malignant Primary; Cerebellar Neoplasm, Malignant; Cerebellar Neoplasms; Cerebellar Neoplasms, Primary; Cerebellar PNET, Childhood; Glioblastoma Multiforme; Glioblastoma of Cerebellum; HSV; Medulloblastoma Recurrent; Neoplasm Malignant; Neoplasm Metastases; Neoplasms; Neoplasms by Histologic Type; Neoplasms by Site; Neoplasms, Brain; Neoplasms, Germ Cell and Embryonal; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Neoplasms, Neuroepithelial; Nervous System Cancer; Nervous System Diseases; Nervous System Neoplasms; Neuroectodermal Tumors; Neuroectodermal Tumors, Primitive; Pediatric Brain Tumor; Primitive Neuroectodermal Tumor (PNET) of Cerebellum; Virus
NCT02457845HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain TumorsCompletedPhase 12016-052020-0613Anaplastic Astrocytoma; Cerebral Primitive Neuroectodermal Tumor; Embryonal Tumor; Glioblastoma; Malignant Glioma; PNET; Supratentorial Neoplasms, Malignant
NCT00157703G207 Followed by Radiation Therapy in Malignant GliomaCompletedPhase 12005-052008-109Malignant Glioma
NCT00028158Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain CancerCompletedPhase 1/22001-1265Astrocytoma; Glioblastoma; Glioma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 33838625Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.The New England journal of medicine2021cited by trial NCT02457845
PMID 32657154Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.Human gene therapy2020name in title: HSV G207
PMID 28319448Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.Human gene therapy. Clinical development2017name in title: HSV G207
PMID 27512668Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy.Oncolytic virotherapy2015name in title: G207
PMID 24572293A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.Molecular therapy : the journal of the American Society of Gene Therapy2014cited by trial NCT00157703
PMID 18957964Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.Molecular therapy : the journal of the American Society of Gene Therapy2009name in title: G207
PMID 10845725Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.Gene therapy2000name in title: G207
Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 38215438The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study.Journal of neurosurgery. Pediatrics2024name in abstract: G207

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 41108331The effect of oncolytic virotherapy on pediatric brain tumor- a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025name in abstract: HSV G207
PMID 38183802Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma.Translational oncology2024name in abstract: HSV G207
PMID 33911216HSV-1 G207 is active in paediatric glioma.Nature reviews. Clinical oncology2021name in title: G207
PMID 30918335Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice.Cancer gene therapy2020name in title: G207
PMID 32096291Folate-conjugated herpes simplex virus for retargeting to tumor cells.The journal of gene medicine2020name in abstract: HSV G207
PMID 30481622Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain Tumors.World neurosurgery2019name in title: G207
PMID 31741780A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition.Oncoimmunology2019name in abstract: HSV G207
PMID 18957963Hypoxia enhances the replication of oncolytic herpes simplex virus.Molecular therapy : the journal of the American Society of Gene Therapy2009name in abstract: HSV G207
PMID 19116635Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication.Molecular therapy : the journal of the American Society of Gene Therapy2009name in title: G207
PMID 17234749Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.Cancer research2007name in abstract: HSV G207
PMID 17505980Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain.Journal of neurovirology2007name in title: G207
PMID 16163378Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.Gene therapy2006name in title: G207
PMID 16475242Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses.The journal of gene medicine2006name in abstract: HSV G207
PMID 16955534Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.The journal of gene medicine2006name in title: G207
PMID 15661558Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.European journal of cancer (Oxford, England : 1990)2005name in title: G207
PMID 15754306Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.The journal of gene medicine2005name in title: G207
PMID 15059970Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207).FASEB journal : official publication of the Federation of American Societies for Experimental Biology2004name in title: G207
PMID 15720798Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis.Neoplasia (New York, N.Y.)2004name in title: G207
PMID 12670897Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma.Cancer research2003name in title: G207
PMID 11857031In situ cancer vaccination with a replication-conditional HSV for the treatment of liver metastasis of colon cancer.Cancer gene therapy2002name in abstract: HSV G207
PMID 11960286Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.Cancer gene therapy2002name in abstract: HSV G207
PMID 12219034Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase.Surgery2002name in title: G207
PMID 12386832Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer.Cancer gene therapy2002name in title: G207
PMID 11257700Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207.The Journal of urology2001name in title: G207
PMID 11312559Therapeutic efficacy of G207 in a novel peripheral nerve sheath tumor model.Experimental neurology2001name in title: G207
PMID 11319903Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters.Molecular therapy : the journal of the American Society of Gene Therapy2001name in title: G207
Unconfirmed matches (74)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 41705010A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy.Cureus2026name in abstract: G207
PMID 41741902Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors.Journal of neuro-oncology2026name in abstract: G207
PMID 40805247Oncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives.Cancers2025name in abstract: G207
PMID 41228258The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management.Cancers2025name in abstract: G207
PMID 38724464Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.Journal for immunotherapy of cancer2024name in abstract: G207
PMID 38806994A viral attack on brain tumors: the potential of oncolytic virus therapy.Journal of neurovirology2024name in abstract: G207
PMID 39239066Synergistic effects of herpes oncolytic virus and cyclophosphamide for recurrent malignant glioma: a narrative review.Annals of medicine and surgery (2012)2024name in abstract: G207
PMID 39850819Rational strategies for designing next-generation oncolytic viruses based on transcriptome analysis of tumor cells infected with oncolytic herpes simplex virus-1.Frontiers in oncology2024name in abstract: G207
PMID 36634220Intraventricular immunovirotherapy; a translational step forward.Oncotarget2023name in abstract: G207
PMID 37749907Oncolytic virotherapies for pediatric tumors.Expert opinion on biological therapy2023name in abstract: G207
PMID 34004331Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.Seminars in cancer biology2022name in abstract: G207
PMID 35093451Gospel of malignant Glioma: Oncolytic virus therapy.Gene2022name in abstract: G207
PMID 35105718Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.Clinical cancer research : an official journal of the American Association for Cancer Research2022name in abstract: G207
PMID 35487285Clinical advances in oncolytic virotherapy for pediatric brain tumors.Pharmacology & therapeutics2022name in abstract: G207
PMID 36239623Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research2022name in abstract: G207
PMID 33663205Uncovering the Effect of pS202/pT205/pS208 Triple Phosphorylations on the Conformational Features of the Key Fragment G192-T212 of Tau Protein.ACS chemical neuroscience2021name in abstract: G207
PMID 29896663Oncolytic Virotherapy by HSV.Advances in experimental medicine and biology2018name in abstract: G207
PMID 30224769Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.Scientific reports2018name in abstract: G207
PMID 30563466Oncolytic herpes simplex virus and immunotherapy.BMC immunology2018name in abstract: G207
PMID 28830653Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease.Journal of autoimmunity2017name in abstract: G207
PMID 26188016Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.Neuro-oncology2016name in abstract: G207
PMID 27215210Characterization and differential expression analysis of Toxocara canis aquaporin-1 gene.Parasitology research2016name in abstract: G207
PMID 27504936Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.The FEBS journal2016name in abstract: G207
PMID 25119379Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.Gene therapy2014name in abstract: G207
PMID 21740360Targeted oncolytic herpes simplex viruses for aggressive cancers.Current pharmaceutical biotechnology2012name in abstract: G207
PMID 22015641Molecular network pathways and functional analysis of tumor signatures associated with development of resistance to viral gene therapy.Cancer gene therapy2012name in abstract: G207
PMID 22379082Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.Journal of virology2012name in abstract: G207
PMID 22299445Heterologously type IV pilus expressed protein of Burkholderia pseudomallei is immunogenic but fails to induce protective immunity in mice.The Southeast Asian journal of tropical medicine and public health2011name in abstract: G207
PMID 19829315Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment.Gene therapy2010name in abstract: G207
PMID 20205051HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases.Current opinion in drug discovery & development2010name in abstract: G207
PMID 19455266Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2009name in abstract: G207
PMID 19526622Relationship between 31P metabolites and oncolytic viral therapy sensitivity in human colorectal cancer xenografts.The British journal of surgery2009name in abstract: G207
PMID 19693098Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.Gene therapy2009name in abstract: G207
PMID 19714803Structural and catalytic roles of residues located in beta13 strand and the following beta-turn loop in Fibrobacter succinogenes 1,3-1,4-beta-D-glucanase.Biochimica et biophysica acta2009name in abstract: G207
PMID 19967103Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2009name in abstract: G207
PMID 17981691Oncolytic virus therapy using genetically engineered herpes simplex viruses.Frontiers in bioscience : a journal and virtual library2008name in abstract: G207
PMID 18316577Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2008name in abstract: G207
PMID 18316582Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research2008name in abstract: G207
PMID 18551144Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication.Cancer gene therapy2008name in abstract: G207
PMID 18988803Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.The American journal of pathology2008name in abstract: G207
PMID 19121697TBK1 does not play a role in the control of in vitro Burkholderia pseudomallei growth.Transactions of the Royal Society of Tropical Medicine and Hygiene2008name in abstract: G207
PMID 16990846Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors.Cancer gene therapy2007name in abstract: G207
PMID 17235305Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.Molecular therapy : the journal of the American Society of Gene Therapy2007name in abstract: G207
PMID 17238803Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.Human gene therapy2007name in abstract: G207
PMID 17613221Oncolytic herpes simplex virus therapy for peripheral nerve tumors.Neurosurgical focus2007name in abstract: G207
PMID 17908985Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.Clinical cancer research : an official journal of the American Association for Cancer Research2007name in abstract: G207
PMID 16179929Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.Cancer gene therapy2006name in abstract: G207
PMID 16391370Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.Journal of the National Cancer Institute2006name in abstract: G207
PMID 16421599Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.Gene therapy2006name in abstract: G207
PMID 16574492Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein.Molecular therapy : the journal of the American Society of Gene Therapy2006name in abstract: G207
PMID 16627219Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2006name in abstract: G207
PMID 17167712Reovirus - possible therapy of cancer.Neoplasma2006name in abstract: G207
PMID 15735042Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.Cancer research2005name in abstract: G207
PMID 15818382The potential of oncolytic virus therapy for pancreatic cancer.Cancer gene therapy2005name in abstract: G207
PMID 16158944Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells.Anticancer research2005name in abstract: G207
PMID 16278413Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research2005name in abstract: G207
PMID 34679293[Insights into a new weapon against cancer: oncolytic viruses].Virologie (Montrouge, France)2005name in abstract: G207
PMID 14770080Augmentation of antitumor immune responses by multiple intratumoral inoculations of replication-conditional HSV and interleukin-12.Journal of immunotherapy (Hagerstown, Md. : 1997)2004name in abstract: G207
PMID 15000342Oncolytic viral therapy and immunotherapy of malignant brain tumors: two potential new approaches of translational research.Annals of medicine2004name in abstract: G207
PMID 15166969Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases.Annals of surgery2004name in abstract: G207
PMID 15185293Effect of murine liver cell proliferation on herpes viral behavior: implications for oncolytic viral therapy.Hepatology (Baltimore, Md.)2004name in abstract: G207
PMID 15300180Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer.Surgery2004name in abstract: G207
PMID 15349105Carcinoembryonic antigen directed herpes viral oncolysis improves selectivity and activity in colorectal cancer.Surgery2004name in abstract: G207
PMID 15383793Utilizing alpha-fetoprotein expression to enhance oncolytic viral therapy in hepatocellular carcinoma.Annals of surgery2004name in abstract: G207
PMID 12942152Immuno-viral therapy as a new approach for the treatment of brain tumors.Drug news & perspectives2003name in abstract: G207
PMID 14530377Targeting platelet-leukocyte interactions: identification of the integrin Mac-1 binding site for the platelet counter receptor glycoprotein Ibalpha.The Journal of experimental medicine2003name in abstract: G207
PMID 14682372Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas.Journal of neuro-oncology2003name in abstract: G207
PMID 11916486Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.Human gene therapy2002name in abstract: G207
PMID 11956088Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.Cancer research2002name in abstract: G207
PMID 12218591Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses.Journal of pediatric hematology/oncology2002name in abstract: G207
PMID 12242723Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.The Prostate2002name in abstract: G207
PMID 12522436Oncolytic herpes simplex virus vectors for cancer virotherapy.Cancer gene therapy2002name in abstract: G207
PMID 11196154In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.Cancer research2001name in abstract: G207
PMID 11306480Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation.Cancer research2001name in abstract: G207

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R01FD006368Ph1 Study of HSV G207 in Pediatric Malignant Cerebellar Tumors IND 16294 01/05/18.UNIVERSITY OF TX MD ANDERSON CAN CTRFRIEDMAN, GREGORY K2019–2026name in title: HSV G207
R44CA250883Phase II Clinical Trial of G207 HSV To Treat Children with High Grade GliomasTREOVIR, INCGILLESPIE, GEORGE YANCEY2020–2023name in title: G207
R01CA217179A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.UNIVERSITY OF ALABAMA AT BIRMINGHAMMARKERT, JAMES M2017–2019name in abstract: HSV G207
R01FD005379Ph1 of HSV G207 and Radiation to Treat Pediatric Brain Tumors IND16294 (12/10/14)UNIVERSITY OF ALABAMA AT BIRMINGHAMFRIEDMAN, GREGORY K2016–2018name in title: HSV G207
M01RR000032CT 2001 A STAGED PHASE I STUDY OF THE TREATMENT OF MALIGNANT GLIOMA WITH G207,UNIVERSITY OF ALABAMA AT BIRMINGHAMMARKERT, JAMES M1999–2007name in title: G207
Unconfirmed matches (18)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

ProjectTitleOrganisationPIYearsLinked by
P01CA163205Project 3: Circumventing extracellular Adenosine barrier to oncolytic virotherapyBRIGHAM AND WOMEN'S HOSPITALKAUR, BALVEEN2023–2026name in project terms: G207
P30CA01314803 - Neuro-OncologyUNIVERSITY OF ALABAMA AT BIRMINGHAMNABORS, LOUIS B2022–2026name in abstract: G207
R01NS146081Targeting RNF2 to Synergize with Oncolytic Immunovirotherapy to Induce Anti-Cancer Immunity in MedulloblastomaUNIVERSITY OF TX MD ANDERSON CAN CTRFRIEDMAN, GREGORY K2026–2026name in abstract: G207
R33NS128191Development of murine glioblastoma model for oncolytic HSV therapyLSU HEALTH SCIENCES CENTERKAUR, BALVEEN2026–2026name in abstract: G207
R61NS128191Development of murine glioblastoma model for oncolytic HSV therapyAUGUSTA UNIVERSITYKAUR, BALVEEN2024–2025name in abstract: G207
U19CA264512An engineered oncolytic herpes virus expressing a full-length α-CD47 mAb for the treatment of GBMBECKMAN RESEARCH INSTITUTE/CITY OF HOPEBADIE, BEHNAM2021–2025name in project terms: G207
UM1CA081457Pediatric Brain Tumor Consortium A multi-institutional consortium devoted to novel phase I and II clinical evaluations of experimental treatment approaches for pediatric CNS tumorsST. JUDE CHILDREN'S RESEARCH HOSPITALONAR-THOMAS, ARZU2025–2025name in project terms: G207
R03NS128449Targeting Acid Ceramidase to Improve the Efficacy of Herpes Oncolytic VirusUNIVERSITY OF ALABAMA AT BIRMINGHAMHJELMELAND, ANITA BORTON2022–2023name in project terms: G207
R33NS112410Optimizing oncolytic virus therapy for glioblastomaAUGUSTA UNIVERSITYKAUR, BALVEEN2022–2022name in abstract: G207
R01CA150153Enhancing viral oncolysis with vasculostatin gene deliveryUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTONKAUR, BALVEEN2016–2020name in abstract: G207
R61NS112410Optimizing oncolytic virus therapy for glioblastomaUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTONKAUR, BALVEEN2019–2020name in abstract: G207
F31CA192453Oncolytic Herpes Simplex Virus Interactions with Glioblastoma Stem CellsHARVARD MEDICAL SCHOOLPETERS, COLE WINSTEAD DYLAN2015–2017name in project terms: G207
P01CA071933Engineered HSV For Treatment of Malignant GliomaUNIVERSITY OF ALABAMA AT BIRMINGHAMWHITLEY, RICHARD J.2009–2013name in abstract: G207
P01NS040923Vector delivery to modify the brain tumor and its microenvironmentUNIVERSITY OF PITTSBURGH AT PITTSBURGHGLORIOSO, JOSEPH C2008–2012name in abstract: G207
P01CA080124Improving Interstitial Transport in TumorsMASSACHUSETTS GENERAL HOSPITALJAIN, RAKESH K.2007–2010name in project terms: G207
R01CA119298Glioma Therapy Using Targeted Oncolytic HSV VectorsUNIVERSITY OF PITTSBURGH AT PITTSBURGHGLORIOSO, JOSEPH C2006–2010name in abstract: G207
R01CA083066IMAGING TRANSGENE EXPRESSION IN GENE THERAPY PROTOCOLSSLOAN-KETTERING INST CAN RESEARCHBLASBERG, RONALD G2002–2004name in abstract: G207
R01NS032677GENETICALLY ENGINEERED VIRUSES FOR BRAIN TUMOR THERAPYMASSACHUSETTS GENERAL HOSPITALMARTUZA, ROBERT L1998–2002name in abstract: G207

Notes

Second-generation oHSV; first-in-human glioma trial 1998-2000 (Markert et al.). Paediatric trials run by the University of Alabama at Birmingham and the Pediatric Brain Tumor Consortium. A planned phase 2 (NCT04482933) was withdrawn.

How to cite

G207 (AXP000074.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000074.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.